healthandpharma4d
KEYTRUDA Receives Priority FDA Review for Perioperative Use in Earlier-Stage Head and Neck Cancer
KEYTRUDA (pembrolizumab) plus standard care for resectable locally advanced head and neck squamous cell carcinoma receives ...
healthandpharma6d
Odronextamab Gains FDA Review for Hard-to-Treat Relapsed/Refractory Follicular Lymphoma
Regeneron Pharmaceuticals, announced that FDA accepted its resubmitted Biologics License Application for odronextamab, a ...
healthandpharma4d
Enhertu Gains EMA’s CHMP Support for HER2-Low Metastatic Breast Cancer Treatment
The European Medicines Agency (EMA) committee (CHMP) has recommended approving trastuzumab deruxtecan (Enhertu), a ...
healthandpharma6d
First-Line Oral SERD, Camizestrant Plus CDK4/6 Inhibition Boosts PFS in ESR1+, HR+/HER2– Breast Cancer
The early findings from the SERENA-6 trial indicate that the investigational oral SERD camizestrant provides a “highly ...